Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
Noble Corporation Secures $1.3 Billion in New Contracts, Strengthening Offshore Drilling Backlog 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
DALLAS and FORT WORTH, Texas, May 16, 2017 -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that Vipin Garg, Ph.D., president and chief executive officer, will present a company overview at the upcoming 2017 UBS Global Healthcare Conference on Tuesday, May 23, 2017 at 3:00 p.m. ET in New York, NY.
A live webcast of the presentation will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODTTM, indicated for the treatment of ADHD in patients 6 years of age and older, is the first approved product using the Company’s extended-release (XR)-orally disintegrating tablet (ODT) technology platform. Neos, which is initially focusing on the treatment of ADHD, has filed New Drug Applications with the U.S. Food and Drug Administration for two other branded product candidates that are XR medications in ODT or oral suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®, an XR oral suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.1
1Tussionex® is a registered trademark of the UCB Group of Companies.
Contacts: Richard Eisenstadt Chief Financial Officer Neos Therapeutics (972) 408-1389 [email protected] Sarah McCabe Vice President Stern Investor Relations, Inc. (212) 362-1200 [email protected]
